aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel functions of tRNA synthetases in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of SSc-ILD and other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Period	TotalRevenue
2015-12-31	N/A
2016-12-31	-$57.85M
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	$2.22M
2020-12-31	$10.46M
2021-12-31	N/A
2022-12-31	$10.39M
2023-12-31	$353.00K
2024-12-31	$235.00K

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATYR	$0.80	+0.04%	0.56M
3
4
5

aTyr Pharma Inc. (ATYR) Revenue History

Revenue Data

Get aTyr Pharma Inc. Data in Excel

More ATYR Financial Data